Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Azilsartan Medoxomil Tablets, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Azurity Pharmaceuticals, Inc., all published on July 31, 2026.
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Azilsartan Medoxomil Tablets, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Azurity Pharmaceuticals, Inc., all published on July 31, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Azurity Pharmaceuticals, Inc.. Shared-story counts are live from our verified record — not editorial picks.
Lupin launches its generic azilsartan medoxomil in the U.S., capturing first-to-file exclusivity for a $53.5 million hypertension drug market. The move strengthens Lupin’s cardiovascular pipeline and could deliver a revenue boost during the 180-day exclusivity window.
Source: prnewswire.com · montrealgazette.com
Azurity Pharmaceuticals, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
